RÉSUMÉ
Pancreatoduodenectomy is a complex surgical procedure with a high rate of morbidity, of which surgical-site infections (SSIs) make a large portion. Reduction of SSI rates is critical to decrease hospital lengths of stay, readmissions, delays in adjuvant therapies, and financial health care burden. Current clinical guidelines recommend the administration of cefoxitin as surgical prophylaxis prior to pancreatoduodenectomy. In April 2023, a randomized controlled trial was published in JAMA which showed that piperacillin-tazobactam as perioperative surgical prophylaxis prior to pancreatoduodenectomy decreased 30 day SSI rates (primary outcome), clinically relevant postoperative pancreatic fistula, postoperative sepsis, and Clostridium difficile infection rates.
Sujet(s)
Antibactériens , Antibioprophylaxie , Duodénopancréatectomie , Infection de plaie opératoire , Humains , Duodénopancréatectomie/effets indésirables , Infection de plaie opératoire/prévention et contrôle , Antibactériens/usage thérapeutique , Antibactériens/administration et posologie , Antibioprophylaxie/méthodes , Céfoxitine/usage thérapeutique , Céfoxitine/administration et posologie , Association de pipéracilline et de tazobactam/usage thérapeutique , Association de pipéracilline et de tazobactam/administration et posologieRÉSUMÉ
Tazobactam/piperacillin and meropenem are commonly used as an empiric treatment in patients with severe bacterial infections. However, few studies have investigated the cause of tazobactam/piperacillin- or meropenem-induced liver injury in them. Our objective was to evaluate the association between tazobactam/piperacillin or meropenem and liver injury in the intensive care unit patients. We evaluated the expression profiles of antibiotics-induced liver injury using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Further, in the retrospective observational study, data of patients who initiated tazobactam/piperacillin or meropenem in the intensive care unit were extracted. In FAERS database, male, age, the fourth-generation cephalosporin, carbapenem, ß-lactam and ß-lactamase inhibitor combination, and complication of sepsis were associated with liver injury (p < 0.001). In the retrospective observational study, multivariate logistic regression analyses indicated that the risk factors for liver injury included male (p = 0.046), administration period ≥ 7 days (p < 0.001), and alanine aminotransferase (p = 0.031). Not only administration period but also sex and alanine aminotransferase should be considered when clinicians conduct the monitoring of liver function in the patients receiving tazobactam/piperacillin or meropenem.
Sujet(s)
Systèmes de signalement des effets indésirables des médicaments , Antibactériens , Lésions hépatiques dues aux substances , Méropénème , Food and Drug Administration (USA) , Humains , Mâle , Lésions hépatiques dues aux substances/épidémiologie , Lésions hépatiques dues aux substances/étiologie , Femelle , Antibactériens/effets indésirables , Études rétrospectives , Adulte d'âge moyen , États-Unis/épidémiologie , Sujet âgé , Méropénème/effets indésirables , Méropénème/usage thérapeutique , Adulte , Association de pipéracilline et de tazobactam/effets indésirables , Facteurs de risque , Unités de soins intensifsRÉSUMÉ
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Most patients with moderate-to-severe disease require long-term antibiotic treatment, or biologic treatments to control their disease. Despite these interventions, relapses are common. This study evaluated the effectiveness of piperacillin/tazobactam treatment in patients with Hurley stage II and III HS who experienced disease flares and did not respond to conventional antibiotic and biologic treatment. Methods: Patients with HS hospitalized at the Department of Dermatology, Sheba Medical Center between August 2021 and January 2023 were retrospectively analyzed. Results: A cohort of ten such patients were treated with piperacillin/tazobactam for 6-21 days. Eight (80%) and two (20%) patients respectively demonstrated 2- and 1-grade improvements, from their baseline HS-Physician Global Assessment score. During the follow-up period, nine patients were monitored. HS Clinical Response (HiSCR) was achieved in six (66.7%) and five (55.6%) patients at the 3- and 6-month follow-up visits, respectively. Conclusions: In conclusion, Piperacillin/tazobactam emerges as a promising therapeutic option for disease flare-up in patients with Hurley stage II and III HS who do not respond to conventional treatment. Thus, piperacillin/tazobactam should be considered as crisis therapy for this patient subset.
Sujet(s)
Antibactériens , Hidrosadénite suppurée , Association de pipéracilline et de tazobactam , Indice de gravité de la maladie , Humains , Hidrosadénite suppurée/traitement médicamenteux , Association de pipéracilline et de tazobactam/usage thérapeutique , Femelle , Mâle , Études rétrospectives , Adulte , Antibactériens/usage thérapeutique , Adulte d'âge moyen , Résultat thérapeutique , Aggravation transitoire des symptômes , Jeune adulteRÉSUMÉ
OBJECTIVES: To investigate clinical outcomes of patients with Pseudomonas endocarditis and identify factors associated with treatment failure. METHODS: Adult patients meeting definitive Duke's criteria for Pseudomonas endocarditis at 11 hospitals were identified between May 2000 and February 2024. Failure was defined as death or microbiological failure by day 42. First-line therapy consisted of cefepime, piperacillin/tazobactam, ceftazidime or ceftolozane/tazobactam alone or in combination. RESULTS: Forty-eight patients met inclusion criteria; 29% were persons who inject drugs and 13% were organ transplant recipients. Pseudomonas aeruginosa was the causative species in 98% of cases. Patients who experienced 42 day cure were more likely to be initially managed with first-line ß-lactam agents compared with those who experienced clinical failure (97% versus 62%, Pâ=â0.004). Treatment with first-line ß-lactams was associated with shorter time to treatment initiation and a lower likelihood of infection due to MDR Pseudomonas spp. In the univariate model, patients who experienced 90 day mortality were more likely to have prosthetic valve endocarditis (57% versus 24%, Pâ=â0.02), an intracardiac complication (36% versus 9%, Pâ=â0.04) and a higher median (IQR) Pitt bacteraemia score [2.5 (2-3.8) versus 1 (0-2), Pâ=â0.048]. Combination therapy did not improve clinical outcomes but did increase the rate of adverse effects resulting in drug discontinuation compared with monotherapy, (21% versus 0%, Pâ=â0.08). CONCLUSIONS: This is the largest study of Pseudomonas endocarditis to date. We identified improved clinical outcomes when cefepime, piperacillin/tazobactam, ceftazidime or ceftolozane/tazobactam were used for initial treatment. We did not identify a clinical benefit for combination treatment.
Sujet(s)
Antibactériens , Endocardite bactérienne , Infections à Pseudomonas , Pseudomonas aeruginosa , Humains , Infections à Pseudomonas/traitement médicamenteux , Infections à Pseudomonas/microbiologie , Infections à Pseudomonas/mortalité , Mâle , Femelle , Adulte d'âge moyen , Antibactériens/usage thérapeutique , Endocardite bactérienne/traitement médicamenteux , Endocardite bactérienne/microbiologie , Endocardite bactérienne/mortalité , Adulte , Sujet âgé , Pseudomonas aeruginosa/effets des médicaments et des substances chimiques , Résultat thérapeutique , Tazobactam/usage thérapeutique , Études rétrospectives , Échec thérapeutique , Association de pipéracilline et de tazobactam/usage thérapeutique , CéphalosporinesRÉSUMÉ
Limited literature exists on chloramphenicol's clinical use. In this retrospective, single-center case-series, we examined 183 chloramphenicol-treated and 81 piperacillin-tazobactam-treated medical patients. Chloramphenicol recipients were older, more debilitated, cognitively impaired, and penicillin allergic, while increased need for inotropics, higher leukocyte count, and higher creatinine levels were notable in the piperacillin-tazobactam group. Pneumonia was the most common indication, with no mortality difference between groups. While acknowledging its antimicrobial activity and potential benefit in specific conditions such as pneumonia, further clinical studies are needed to assess the role of chloramphenicol in the setting where other alternatives are available.
Sujet(s)
Antibactériens , Chloramphénicol , Humains , Chloramphénicol/usage thérapeutique , Études rétrospectives , Antibactériens/usage thérapeutique , Mâle , Sujet âgé , Femelle , Adulte d'âge moyen , Sujet âgé de 80 ans ou plus , Hospitalisation/statistiques et données numériques , Résultat thérapeutique , Association de pipéracilline et de tazobactam/usage thérapeutique , Adulte , DémographieRÉSUMÉ
The standard treatment for an infected pressure ulcer (PU) with osteomyelitis is debridement, wound coverage and antibiotic administration. However, systemic administration of antibiotics in patients with osteomyelitis is controversial, and the optimal treatment duration for chronic osteomyelitis has not been standardised. We report a case of sudden severe thrombocytopenia induced by piperacillin/tazobactam (PIPC/TAZ) in a patient with PU-related osteomyelitis. A 57-year-old male patient with paraplegia, using a wheelchair full-time, presented to our plastic surgery department with infection of a stage IV hard-to-heal ischial PU. We surgically debrided the necrotising tissue and raised an ipsilateral biceps femoris musculocutaneous propeller flap for wound coverage. Polymicrobial infections, including Pseudomonas aeruginosa, were detected in the bone biopsy sample; therefore, systemic PIPC/TAZ was administered for the osteomyelitis. Unexpectedly, during the next 12 days of antibiotic administration, the patient's platelet count acutely dropped to 1×103/µl over three days. Based on a series of examinations, PIPC/TAZ was suspected to be the most likely cause of the severe thrombocytopenia. After drug discontinuation, the thrombocytopenia gradually improved. PIPC/TAZ is one of the most widely used antibiotic combinations in the plastic surgery field; it is conventionally administered for hard-to-heal wounds such as PUs and diabetic foot. The present case suggests that surgeons must take special precautions for patients undergoing PIPC/TAZ treatment. In this report, PIPC/TAZ-induced thrombocytopenia and the efficacy of antibiotic treatment for PU-related osteomyelitis are discussed in light of the available literature.
Sujet(s)
Antibactériens , Ostéomyélite , Association de pipéracilline et de tazobactam , Escarre , Thrombopénie , Humains , Mâle , Adulte d'âge moyen , Escarre/traitement médicamenteux , Association de pipéracilline et de tazobactam/effets indésirables , Association de pipéracilline et de tazobactam/usage thérapeutique , Ostéomyélite/traitement médicamenteux , Thrombopénie/induit chimiquement , Antibactériens/effets indésirables , Antibactériens/usage thérapeutique , Pipéracilline/effets indésirables , Pipéracilline/usage thérapeutique , Infections à Pseudomonas/traitement médicamenteux , Acide pénicillanique/analogues et dérivés , Acide pénicillanique/effets indésirables , Acide pénicillanique/usage thérapeutique , DébridementRÉSUMÉ
Cefepime and piperacillin/tazobactam are antimicrobials recommended by IDSA/ATS guidelines for the empirical management of patients admitted to the intensive care unit (ICU) with community-acquired pneumonia (CAP). Concerns have been raised about which should be used in clinical practice. This study aims to compare the effect of cefepime and piperacillin/tazobactam in critically ill CAP patients through a targeted maximum likelihood estimation (TMLE). A total of 2026 ICU-admitted patients with CAP were included. Among them, (47%) presented respiratory failure, and (27%) developed septic shock. A total of (68%) received cefepime and (32%) piperacillin/tazobactam-based treatment. After running the TMLE, we found that cefepime and piperacillin/tazobactam-based treatments have comparable 28-day, hospital, and ICU mortality. Additionally, age, PTT, serum potassium and temperature were associated with preferring cefepime over piperacillin/tazobactam (OR 1.14 95% CI [1.01-1.27], p = 0.03), (OR 1.14 95% CI [1.03-1.26], p = 0.009), (OR 1.1 95% CI [1.01-1.22], p = 0.039) and (OR 1.13 95% CI [1.03-1.24], p = 0.014)]. Our study found a similar mortality rate among ICU-admitted CAP patients treated with cefepime and piperacillin/tazobactam. Clinicians may consider factors such as availability and safety profiles when making treatment decisions.
Sujet(s)
Antibactériens , Céfépime , Infections communautaires , Maladie grave , Unités de soins intensifs , Association de pipéracilline et de tazobactam , Humains , Céfépime/usage thérapeutique , Céfépime/administration et posologie , Infections communautaires/traitement médicamenteux , Infections communautaires/mortalité , Association de pipéracilline et de tazobactam/usage thérapeutique , Mâle , Femelle , Sujet âgé , Adulte d'âge moyen , Antibactériens/usage thérapeutique , Fonctions de vraisemblance , Pneumopathie infectieuse/traitement médicamenteux , Pneumopathie infectieuse/mortalité , Pipéracilline/usage thérapeutiqueRÉSUMÉ
BACKGROUND/AIM: We evaluated the usefulness of prophylactic mini-tracheostomy (PMT) and perioperative administration of tazobactam/piperacillin (TAZ/PIPC) in high-risk patients after esophagectomy. PATIENTS AND METHODS: We retrospectively studied 89 consecutive high-risk patients who underwent esophagectomy for esophageal cancer between January 2013 and December 2021. We defined patients with two or more of the following factors as high risk: age ≥70 years, performance status ≥1, respiratory dysfunction, liver dysfunction, cardiac dysfunction, renal dysfunction, diabetes mellitus, albumin <3.5 g/dl, and Brinkman index >600. Standard management was administered to the first 50 patients (standard group). PMT and TAZ/PIPC were administered to the next 39 patients (combination group). Patient characteristics and short-term outcomes were compared before and after propensity-score matching. RESULTS: Before propensity-score matching, 24-hour urine creatinine clearance, retrosternal route, 3-field lymph node dissection, and open abdominal approach were more common, postoperative pneumonia (13% vs. 36%, p=0.045) and complications of grade ≥3b (2.6% vs. 22%, p=0.01) were less frequent, and the postoperative hospital stay was shorter (median: 23 vs. 28 days, p=0.022) in the combination group than in the standard group. In propensity-score matching, patient characteristics, except for 24-h creatinine clearance and reconstructive route, were matched for 23 paired patients. Postoperative pneumonia (8.7% vs. 39%, p=0.035) and complications of grade ≥3b (0% vs. 26%, p=0.022) were less frequent and postoperative hospital stay was shorter (median: 22 vs. 25 days, p=0.021) in the combination group than in the standard group. CONCLUSION: PMT with TAZ/PIPC can potentially prevent postoperative pneumonia in high-risk patients after esophagectomy.
Sujet(s)
Tumeurs de l'oesophage , Oesophagectomie , Association de pipéracilline et de tazobactam , Pneumopathie infectieuse , Complications postopératoires , Humains , Mâle , Femelle , Sujet âgé , Oesophagectomie/effets indésirables , Oesophagectomie/méthodes , Tumeurs de l'oesophage/chirurgie , Pneumopathie infectieuse/prévention et contrôle , Pneumopathie infectieuse/étiologie , Pneumopathie infectieuse/épidémiologie , Association de pipéracilline et de tazobactam/usage thérapeutique , Association de pipéracilline et de tazobactam/administration et posologie , Adulte d'âge moyen , Complications postopératoires/prévention et contrôle , Complications postopératoires/étiologie , Antibactériens/usage thérapeutique , Antibactériens/administration et posologie , Études rétrospectives , Facteurs de risqueRÉSUMÉ
BACKGROUND: Pancreatoduodenectomy is associated with an increased incidence of surgical-site infections, often leading to a significant rise in morbidity and mortality. This trend underlines the inadequacy of traditional antibiotic prophylaxis strategies. Hence, the aim of this meta-analysis was to assess the outcomes of antimicrobial prophylaxis, comparing piperacillin/tazobactam with traditional antibiotics. METHODS: Upon registering in PROSPERO, the international prospective register of systematic reviews (CRD42023479100), a systematic search of various databases was conducted over the interval 2000-2023. This inclusive search encompassed a wide range of study types, including prospective and retrospective cohorts and RCTs. The subsequent data analysis was carried out utilizing RevMan 5.4. RESULTS: A total of eight studies involving 2382 patients who underwent pancreatoduodenectomy and received either piperacillin/tazobactam (1196 patients) or traditional antibiotics (1186 patients) as antibiotic prophylaxis during surgery were included in the meta-analysis. Patients in the piperacillin/tazobactam group had significantly reduced incidences of surgical-site infections (OR 0.43 (95% c.i. 0.30 to 0.62); P < 0.00001) and major surgical complications (Clavien-Dindo grade greater than or equal to III) (OR 0.61 (95% c.i. 0.45 to 0.81); P = 0.0008). Subgroup analysis of surgical-site infections highlighted significantly reduced incidences of superficial surgical-site infections (OR 0.34 (95% c.i. 0.14 to 0.84); P = 0.02) and organ/space surgical-site infections (OR 0.47 (95% c.i. 0.28 to 0.78); P = 0.004) in the piperacillin/tazobactam group. Further, the analysis demonstrated significantly lower incidences of clinically relevant postoperative pancreatic fistulas (grades B and C) (OR 0.67 (95% c.i. 0.53 to 0.83); P = 0.0003) and mortality (OR 0.51 (95% c.i. 0.28 to 0.91); P = 0.02) in the piperacillin/tazobactam group. CONCLUSION: Piperacillin/tazobactam as antimicrobial prophylaxis significantly lowers the risk of postoperative surgical-site infections, major surgical complications (complications classified as Clavien-Dindo grade greater than or equal to III), clinically relevant postoperative pancreatic fistulas (grades B and C), and mortality, hence supporting the implementation of piperacillin/tazobactam for surgical prophylaxis in current practice.
Sujet(s)
Antibactériens , Antibioprophylaxie , Duodénopancréatectomie , Association de pipéracilline et de tazobactam , Infection de plaie opératoire , Humains , Duodénopancréatectomie/effets indésirables , Association de pipéracilline et de tazobactam/usage thérapeutique , Infection de plaie opératoire/prévention et contrôle , Antibactériens/usage thérapeutique , Pipéracilline/usage thérapeutiqueSujet(s)
Antibactériens , Hypersensibilité médicamenteuse , Association de pipéracilline et de tazobactam , bêta-Lactames , Humains , Hypersensibilité médicamenteuse/diagnostic , Hypersensibilité médicamenteuse/immunologie , Hypersensibilité médicamenteuse/étiologie , Association de pipéracilline et de tazobactam/effets indésirables , bêta-Lactames/effets indésirables , bêta-Lactames/immunologie , Mâle , Femelle , Antibactériens/effets indésirables , Antibactériens/immunologie , Adulte d'âge moyen , Sujet âgé , Étiquetage de médicament , Adulte , Pipéracilline/effets indésirables , Pipéracilline/immunologieRÉSUMÉ
OBJECTIVE: Acute graft pyelonephritis (AGPN) is the most frequent infectious complication in kidney transplant recipients (KTR). The treatment of acute community-acquired (CA) pyelonephritis is based on third-generation cephalosporins (3GC) and fluoroquinolones. Cefepime or a piperacillin-tazobactam combination are more often used in healthcare-associated (HCA) infections. However, these recommendations do not consider the resistance observed in KTRs. The objective of our study was to define the most appropriate empirical antibiotherapy for AGPN in KTRs according to the CA and HCA settings. To answer this question, we assessed the prevalence of resistance to different antibiotics usually recommended for urinary tract infections (UTIs) in the general population. METHODS: Observational, retrospective, multicenter study covering all episodes of AGPN occurring in hospitalized KTRs in 2019. RESULTS: A total of 210 patients were included in 7 centers and 244 episodes of AGPN were analyzed (158 CA-AGPN and 86 HCA-AGPN). The prevalence of 3GC and fluoroquinolone resistance was 23 % (n = 36) and 30 % (n = 50) in CA infections (n = 158), and 47 % (n = 40) and 31 % (n = 27) in HCA infections (n = 86), respectively. Cefepime resistance rate was 19 % (n = 30) in CA-AGPN and 29 % (n = 25) in HCA-AGPN. Piperacillin-tazobactam combination had resistance rates > 15 % in both CA and HCA infections. The only antimicrobials with resistance rates < 10 % were aminoglycosides and carbapenems. CONCLUSION: None of the antibiotics recommended in empirical treatment in UTIs has shown a resistance rate of less than 10% with regard to AGPN. Therefore, none of them should be used as monotherapy. A combination therapy including amikacin could be an appropriate strategy in this setting.
Sujet(s)
Antibactériens , Transplantation rénale , Pyélonéphrite , Humains , Études rétrospectives , Antibactériens/usage thérapeutique , Pyélonéphrite/traitement médicamenteux , Mâle , Femelle , Adulte d'âge moyen , Transplantation rénale/effets indésirables , Adulte , Maladie aigüe , Infections communautaires/traitement médicamenteux , Infections urinaires/traitement médicamenteux , Association de pipéracilline et de tazobactam/usage thérapeutique , Sujet âgé , Fluoroquinolones/usage thérapeutique , Céphalosporines/usage thérapeutique , Résistance bactérienne aux médicaments , Tests de sensibilité microbienne , Infection croisée/traitement médicamenteuxRÉSUMÉ
Patients with hematological malignancies (HM) often receive tazobactam/piperacillin (TAZ/PIPC) and glycopeptide antibiotics for febrile neutropenia. The effect of concomitant use of TAZ/PIPC on risk of teicoplanin (TEIC)-associated acute kidney injury (AKI) remains unclear. We investigated the impact of concomitant TAZ/PIPC use on TEIC-associated AKI in HM patients and identified the risk factors. In this retrospective, single-center, observational cohort study, 203 patients received TEIC, 176 of whom satisfied the selection criteria and were divided into TEIC cohort (no TAZ/PIPC; n = 118) and TEIC + TAZ/PIPC cohort (n = 58). AKI was defined as serum creatinine increase ≥0.3 mg/dL within 48 h or ≥50% from baseline. Incidence of AKI in TEIC cohort before and after propensity score matching was 9.3 and 5.9%, respectively, and that in TEIC + TAZ/PIPC cohort was 10.3 and 11.8%. AKI incidence and risk were not significantly different between two cohorts before (p = 0.829; odds ratio (OR) 1.122, 95% confidence interval (CI) 0.393-3.202) and after matching (p = 0.244; OR 2.133, 95% CI 0.503-9.043). Logistic regression analysis with factors clinically or mechanistically potentially related to TEIC-associated AKI, including concomitant TAZ/PIPC use, as independent variables identified baseline hemoglobin level as the only significant risk factor for TEIC-associated AKI (p = 0.011; OR 0.484, 95% CI 0.276-0.848). In HM patients treated with TEIC, concomitant TAZ/PIPC use did not increase AKI risk whereas lower hemoglobin levels had higher risk for TEIC-associated AKI development, suggesting the necessity to monitor serum creatinine when using TEIC in patients with anemia.
Sujet(s)
Atteinte rénale aigüe , Antibactériens , Tumeurs hématologiques , Association de pipéracilline et de tazobactam , Téicoplanine , Humains , Atteinte rénale aigüe/induit chimiquement , Atteinte rénale aigüe/épidémiologie , Atteinte rénale aigüe/sang , Mâle , Téicoplanine/effets indésirables , Téicoplanine/administration et posologie , Femelle , Adulte d'âge moyen , Tumeurs hématologiques/traitement médicamenteux , Tumeurs hématologiques/complications , Association de pipéracilline et de tazobactam/effets indésirables , Facteurs de risque , Antibactériens/effets indésirables , Études rétrospectives , Sujet âgé , AdulteRÉSUMÉ
BACKGROUND: Piperacillin/tazobactam may be associated with less favourable outcomes than carbapenems in patients with severe bacterial infections, but the certainty of evidence is low. METHODS: The Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) trial is an investigator-initiated, international, parallel-group, randomised, open-label, adaptive clinical trial with an integrated feasibility phase. We will randomise adult, critically ill patients with sepsis to empirical treatment with meropenem or piperacillin/tazobactam for up to 30 days. The primary outcome is 30-day all-cause mortality. The secondary outcomes are serious adverse reactions within 30 days; isolation precautions due to resistant bacteria within 30 days; days alive without life support and days alive and out of hospital within 30 and 90 days; 90- and 180-day all-cause mortality and 180-day health-related quality of life. EMPRESS will use Bayesian statistical models with weak to somewhat sceptical neutral priors. Adaptive analyses will be conducted after follow-up of the primary outcome for the first 400 participants concludes and after every 300 subsequent participants, with adaptive stopping for superiority/inferiority and practical equivalence (absolute risk difference <2.5%-points) and response-adaptive randomisation. The expected sample sizes in scenarios with no, small or large differences are 5189, 5859 and 2570 participants, with maximum 14,000 participants and ≥99% probability of conclusiveness across all scenarios. CONCLUSIONS: EMPRESS will compare the effects of empirical meropenem against piperacillin/tazobactam in adult, critically ill patients with sepsis. Due to the pragmatic, adaptive design with high probability of conclusiveness, the trial results are expected to directly inform clinical practice.
Sujet(s)
Antibactériens , Méropénème , Association de pipéracilline et de tazobactam , Sepsie , Humains , Méropénème/usage thérapeutique , Méropénème/administration et posologie , Sepsie/traitement médicamenteux , Sepsie/mortalité , Association de pipéracilline et de tazobactam/usage thérapeutique , Antibactériens/usage thérapeutique , Antibactériens/administration et posologie , Adulte , Maladie grave , MâleRÉSUMÉ
Importance: Experimental and observational studies have suggested that empirical treatment for bacterial sepsis with antianaerobic antibiotics (eg, piperacillin-tazobactam) is associated with adverse outcomes compared with anaerobe-sparing antibiotics (eg, cefepime). However, a recent pragmatic clinical trial of piperacillin-tazobactam and cefepime showed no difference in short-term outcomes at 14 days. Further studies are needed to help clarify the empirical use of these agents. Objective: To examine the use of piperacillin-tazobactam compared with cefepime in 90-day mortality in patients treated empirically for sepsis, using instrumental variable analysis of a 15-month piperacillin-tazobactam shortage. Design, Setting, and Participants: In a retrospective cohort study, hospital admissions at the University of Michigan from July 1, 2014, to December 31, 2018, including a piperacillin-tazobactam shortage period from June 12, 2015, to September 18, 2016, were examined. Adult patients with suspected sepsis treated with vancomycin and either piperacillin-tazobactam or cefepime for conditions with presumed equipoise between piperacillin-tazobactam and cefepime were included in the study. Data analysis was conducted from December 17, 2022, to April 11, 2023. Main Outcomes and Measures: The primary outcome was 90-day mortality. Secondary outcomes included organ failure-free, ventilator-free, and vasopressor-free days. The 15-month piperacillin-tazobactam shortage period was used as an instrumental variable for unmeasured confounding in antibiotic selection. Results: Among 7569 patients (4174 men [55%]; median age, 63 [IQR 52-73] years) with sepsis meeting study eligibility, 4523 were treated with vancomycin and piperacillin-tazobactam and 3046 were treated with vancomycin and cefepime. Of patients who received piperacillin-tazobactam, only 152 (3%) received it during the shortage. Treatment groups did not differ significantly in age, Charlson Comorbidity Index score, Sequential Organ Failure Assessment score, or time to antibiotic administration. In an instrumental variable analysis, piperacillin-tazobactam was associated with an absolute mortality increase of 5.0% at 90 days (95% CI, 1.9%-8.1%) and 2.1 (95% CI, 1.4-2.7) fewer organ failure-free days, 1.1 (95% CI, 0.57-1.62) fewer ventilator-free days, and 1.5 (95% CI, 1.01-2.01) fewer vasopressor-free days. Conclusions and Relevance: Among patients with suspected sepsis and no clear indication for antianaerobic coverage, administration of piperacillin-tazobactam was associated with higher mortality and increased duration of organ dysfunction compared with cefepime. These findings suggest that the widespread use of empirical antianaerobic antibiotics in sepsis may be harmful.
Sujet(s)
Antibactériens , Céfépime , Association de pipéracilline et de tazobactam , Sepsie , Humains , Céfépime/administration et posologie , Céfépime/usage thérapeutique , Association de pipéracilline et de tazobactam/administration et posologie , Association de pipéracilline et de tazobactam/usage thérapeutique , Mâle , Antibactériens/administration et posologie , Antibactériens/usage thérapeutique , Femelle , Sepsie/traitement médicamenteux , Sepsie/mortalité , Études rétrospectives , Sujet âgé , Adulte d'âge moyenRÉSUMÉ
PURPOSE: The study explores the impact of significant interpretative breakpoint changes for aminoglycosides and piperacillin-tazobactam in Enterobacterales and Pseudomonas aeruginosa, considering PK/PD, clinical data, and susceptibility on clinical reporting and use. PROCEDURE: Between January 2021 and June 2023, a total of 189,583 samples were processed for bacterial pathogens and antimicrobial susceptibility testing was performed using disc diffusion method/VITEK® 2 Compact system/broth microdilution. WHONET software was utilised to capture and analyse the changes in the interpretation of disc diffusion method, following updates to CLSI M100 documents in comparison to previous editions. Antimicrobial consumption data was collected and interpreted as DDD/100 bed days using AMC tool software. Here, we present data for 13,615 members of Order Enterobacterales and 1793 Pseudomonas aeruginosa isolates. FINDING: Enterobacterales exhibited a significant susceptibility drop of 14.7% for gentamicin and 21.7% for amikacin. Pseudomonas aeruginosa showed an increase in isolates with intermediate tobramycin susceptibility, from 0.6% to 29.7%, with relatively minor changes in piperacillin-tazobactam interpretation. CONCLUSION: The changes indicate a shift toward increased 'resistance' and 'intermediate susceptibility' for these antibiotics, emphasizing the need for cautious use and leveraging PK/PD knowledge for improved antibiotic utilization, patient outcomes, and antimicrobial stewardship.
Sujet(s)
Aminosides , Antibactériens , Association de pipéracilline et de tazobactam , Pseudomonas aeruginosa , Association de pipéracilline et de tazobactam/pharmacologie , Association de pipéracilline et de tazobactam/usage thérapeutique , Humains , Antibactériens/pharmacologie , Pseudomonas aeruginosa/effets des médicaments et des substances chimiques , Aminosides/pharmacologie , Inde , Tests d'agents antimicrobiens par diffusion à partir de disques/méthodes , Enterobacteriaceae/effets des médicaments et des substances chimiques , Tests de sensibilité microbienne , Amikacine/pharmacologieRÉSUMÉ
BACKGROUND: A small proportion of Escherichia coli and Klebsiella pneumoniae demonstrate in vitro non-susceptibility to piperacillin/tazobactam but retain susceptibility to ceftriaxone. Uncertainty remains regarding how best to treat these isolates. OBJECTIVES: We sought to compare clinical outcomes between patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection receiving definitive therapy with ceftriaxone versus an alternative effective antibiotic. METHODS: We retrospectively identified patients with a positive blood culture for piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae between 1 January 2013 and 31 December 2022. Patients were divided into one of two definitive treatment groups: ceftriaxone or alternative effective antibiotic. Our primary outcome was a composite of 90â day all-cause mortality, hospital readmission, or recurrence of infection. We used Cox proportional hazards models to compare time with the composite outcome between groups. RESULTS: Sixty-two patients were included in our analysis. Overall, median age was 63â years (IQR 49.5-71.0), the most common source of infection was intra-abdominal (25/62; 40.3%) and the median total duration of therapy was 12.0â days (IQR 9.0-16.8). A total of 9/22 (40.9%) patients in the ceftriaxone treatment group and 18/40 (45.0%) patients in the alternative effective antibiotic group met the composite endpoint. In an adjusted time-to-event analysis, there was no difference in the composite endpoint between groups (HR 0.67, 95% CI 0.30-1.50). The adjusted Bayesian posterior probability that the HR was less than or equal to 1 (i.e. ceftriaxone is as good or better than alternative therapy) was 85%. CONCLUSIONS: These findings suggest that ceftriaxone can be used to effectively treat bloodstream infections with E. coli or K. pneumoniae that are non-susceptible to piperacillin/tazobactam but susceptible to ceftriaxone.
Sujet(s)
Antibactériens , Bactériémie , Ceftriaxone , Infections à Escherichia coli , Escherichia coli , Infections à Klebsiella , Klebsiella pneumoniae , Tests de sensibilité microbienne , Association de pipéracilline et de tazobactam , Humains , Ceftriaxone/usage thérapeutique , Ceftriaxone/pharmacologie , Klebsiella pneumoniae/effets des médicaments et des substances chimiques , Klebsiella pneumoniae/isolement et purification , Adulte d'âge moyen , Mâle , Femelle , Études rétrospectives , Sujet âgé , Antibactériens/usage thérapeutique , Antibactériens/pharmacologie , Association de pipéracilline et de tazobactam/usage thérapeutique , Association de pipéracilline et de tazobactam/pharmacologie , Escherichia coli/effets des médicaments et des substances chimiques , Escherichia coli/isolement et purification , Bactériémie/traitement médicamenteux , Bactériémie/microbiologie , Bactériémie/mortalité , Infections à Klebsiella/traitement médicamenteux , Infections à Klebsiella/microbiologie , Infections à Klebsiella/mortalité , Infections à Escherichia coli/traitement médicamenteux , Infections à Escherichia coli/microbiologie , Résultat thérapeutiqueRÉSUMÉ
INTRODUCTION: Hypernatremia is a common problem among patients with severe burn injuries and seems to be associated with an unfavorable clinical outcome. The current study was designed to evaluate the impact of antibiotics with a high proportion of sodium on this phenomenon. METHODS: All admissions to our burn center from 01/2017 till 06/2023 were retrospectively screened. All patients aged >18 years which suffered from at least 20 % total body surface burned area (TBSA) 2nd degree burn injuries or more than 10 % TBSA when including areas of 3rd degree burn injuries were included. The course of the serum Na-level was analyzed from two days before till two days after the start of the antibiotic treatment. Ampicillin/sulbactam, cefazoline and piperacillin/tazobactam were classified as high-dose sodium antibiotics (HPS), meropenem and vancomycin as low-dose sodium antibiotics (LPS). RESULTS: 120 patients met the inclusion criteria. A significant increase of the serum Na was detectable in the HPS group on day 1 and 2 after initiating the antibiotic treatment (n = 64, day 1: 2,1 (SD 4,18) mmol/l, p < 0,001; day 2: 2,44 (SD 5,26) mmol/l, p < 0,001) while no significant changes were detectable in the LPS group (n = 21, day 1: 0,18 (SD 7,45) mmol/l, p = 0,91; day 2: -0,27 (SD 7,44) mmol/l, p = 0,87). This effect was further aggravated when analyzing only the HPS patients with a TBSA ≥30 % (n = 33; day 1: 2,93 (SD 4,68) mmol/l, p = 0,002; day 2: 3,41 (SD 5,9) mmol/l, p = 0,003). CONCLUSION: The amount of sodium in antibiotics seems to have a relevant impact on the serum Na during the early stages of severe burn injury. Therefore, this aspect should be taken into account when searching for the most appropriate antibiotic treatment for patients with severe burn injury, especially when being at acute risk for a clinical relevant hypernatremia.
Sujet(s)
Antibactériens , Brûlures , Hypernatrémie , Humains , Hypernatrémie/sang , Antibactériens/usage thérapeutique , Mâle , Femelle , Brûlures/complications , Brûlures/traitement médicamenteux , Études rétrospectives , Adulte , Adulte d'âge moyen , Sodium/sang , Association de pipéracilline et de tazobactam/usage thérapeutique , Résultat thérapeutique , Sujet âgé , Vancomycine/usage thérapeutique , Sulbactam/usage thérapeutiqueSujet(s)
Antibactériens , Fièvre , Abcès amibien du foie , Association de pipéracilline et de tazobactam , Humains , Mâle , Association de pipéracilline et de tazobactam/usage thérapeutique , Association de pipéracilline et de tazobactam/effets indésirables , Antibactériens/effets indésirables , Antibactériens/usage thérapeutique , Abcès amibien du foie/traitement médicamenteux , Adulte , Pipéracilline/effets indésirables , Pipéracilline/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Preoperative antibiotic options for pancreaticoduodenectomy (PD) include cefoxitin (CX), piperacillin-tazobactam (PT), or combined cefazolin and metronidazole (CM). Recent studies suggest the superiority of PT over CX, but evidence for CM is unclear. OBJECTIVE: To explore the impact of preoperative antibiotic selection (CM vs. PT and CX vs. PT) on the development of surgical site infections (SSI). METHODS: Consecutive adult patients at one institution who underwent PD from November 2017 to December 2021 and received either CM, PT, or CX preoperatively, were included. The primary outcome was SSI. Secondary outcomes included postoperative infections and clinically significant postoperative pancreatic fistula (POPF). Logistic regression models were used. RESULTS: Among 127 patients included in the study, PT, CM, and CX were administered in 46 (36.2%), 44 (34.6%), and 37 (29.4%) patients, respectively. There were 32 (27.1%) SSI, 20 (36.1%) infections, and 21 (22.9%) POPF events. PT use was associated with reduced risk of SSI compared to CX (OR: 0.32, 95% CI: 0.11-0.89, p = 0.03), but there was no difference as compared to CM (OR: 0.75, 95% CI: 0.27-2.13, p = 0.59). There were no differences in secondary outcomes. CONCLUSION: PT reduced SSI rates compared to CX but was no different to CM among patients undergoing PD at our center.